This narrative provides an excellent case study in how political hyperbole, medical science, and media interpretation can collide to create massive public confusion. By looking closely at the mechanics of the legislative achievement in question, it becomes easy to separate the literal text of the law from the dramatic rhetoric surrounding it.
The Right to Try Act: Mechanics vs. Rhetoric
At the core of this entire controversy is a fundamental conflation of a real legislative milestone with an impossible biological feat. The table below breaks down the reality of the policy versus the sensationalized claims that have fueled recent public debate.
| Feature | Legislative Reality (Right to Try Act) | Sensationalized Claim / Rhetoric |
| Target Population | Terminally ill patients who have exhausted all approved treatment options. | Individuals who have been pronounced medically deceased. |
| Prerequisites | The experimental drug must have successfully passed Phase I clinical safety testing. | Rapid-fire, unchecked testing bypassing traditional safety regulations. |
| FDA Status | The drug is still in the developmental pipeline and has not received final FDA approval. | A “secret” or “ultimate” solution fully possessed by the government. |
| Biological Objective | To offer a potential therapeutic extension of life or symptom management. | To reverse the absolute cessation of brain and cardiovascular activity (resurrection). |
The Legal Framework: Signed into law in May 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act allows eligible patients to bypass the FDA’s traditional expanded access (“compassionate use”) program to request experimental therapies directly from drug manufacturers.
Understanding the Scientific Reality
From a medical perspective, the dividing line between an experimental therapy and an impossible medical claim is absolute:
- Phase I Testing Is Mandatory: Under federal law, no patient can access a drug under “Right to Try” unless it has already been proven safe for human consumption in initial clinical trials. It does not allow for entirely untested or rogue chemical experimentation.
- Biological Death is Irreversible: Medical science holds rigid definitions for biological death, involving the permanent cessation of circulatory, respiratory, or entire brain functions. No experimental medication in existence or development possesses the capability to reverse biological death once it has occurred.
When public communication blurs the lines between experimental options for terminal illnesses and the supernatural promise of resurrection, it inadvertently complicates the work of public health institutions. Fostering a clear, literal understanding of medical legislation ensures that terminally ill patients and their families possess realistic expectations regarding their care options.
For a look back at the actual legislative moment that sparked this ongoing policy discussion, you can watch this archival news coverage of the Trump signs “Right to Try” Act on experimental drugs which documents the original context, intent, and bipartisan bill signing ceremony at the White House.
